Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Up 76.0% in January

Rein Therapeutics Inc. (NASDAQ:RNTX) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 351,493 shares, an increase of 76.0% from the December 31st total of 199,688 shares. Approximately 1.4% of the company’s shares are sold short. Based on an average trading volume of 131,187 shares, the days-to-cover ratio is currently 2.7 days. Based on an average trading volume of 131,187 shares, the days-to-cover ratio is currently 2.7 days. Approximately 1.4% of the company’s shares are sold short.

Analysts Set New Price Targets

Several brokerages recently issued reports on RNTX. Brookline Capital Management downgraded Rein Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. Wall Street Zen lowered shares of Rein Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Rein Therapeutics in a report on Thursday, January 22nd. Citigroup cut shares of Rein Therapeutics to a “hold” rating in a research report on Wednesday, January 21st. Finally, Loop Capital set a $6.00 target price on shares of Rein Therapeutics in a research report on Monday, November 3rd. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $8.00.

Insider Buying and Selling

In related news, major shareholder Voss Capital, Lp acquired 104,183 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The shares were acquired at an average price of $1.22 per share, with a total value of $127,103.26. Following the acquisition, the insider owned 926,441 shares of the company’s stock, valued at approximately $1,130,258.02. This trade represents a 12.67% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of RNTX. ABS Direct Equity Fund LLC bought a new position in Rein Therapeutics during the 4th quarter valued at approximately $145,000. Voss Capital LP lifted its holdings in shares of Rein Therapeutics by 86.0% in the 3rd quarter. Voss Capital LP now owns 2,666,532 shares of the company’s stock worth $3,053,000 after buying an additional 1,232,846 shares during the period. Susquehanna International Group LLP acquired a new stake in Rein Therapeutics in the third quarter worth about $35,000. Prosight Management LP boosted its position in Rein Therapeutics by 32.7% in the 3rd quarter. Prosight Management LP now owns 567,898 shares of the company’s stock worth $650,000 after purchasing an additional 139,979 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Rein Therapeutics by 32.2% in the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock worth $1,338,000 after buying an additional 284,300 shares in the last quarter. Institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Price Performance

Rein Therapeutics stock traded down $0.13 during midday trading on Friday, hitting $1.30. 135,102 shares of the stock were exchanged, compared to its average volume of 128,931. Rein Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $2.96. The stock’s 50-day simple moving average is $1.34 and its 200 day simple moving average is $1.31.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Sell-side analysts anticipate that Rein Therapeutics will post -1.56 earnings per share for the current year.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.